PDCD1 and cancer: BMS-986016 (Relatlimab), the first IgG4 monoclonal antibody developed to target LAG-3, has been clinically tested in a variety of cancers and has been shown to be effective in combination with Nivolumab in advanced melanoma patients treated with anti-PD-1/anti-PD-L1 therapy.